Navigation Links
Hospira Launches Generic Oxaliplatin Injection
Date:8/11/2009

LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States. The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin injection is one of the first generic versions of this drug to come in solution form. The innovator drug is also in solution form. Oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor, and in the treatment of advanced colorectal cancer.

"Hospira's launch of oxaliplatin injection in solution form gives our customers a generic alternative of this critical medication in the formulation they seek," said Sue Hazelwood, vice president and general manager, alternate site, U.S., Hospira. "This is another example of Hospira's dedication to providing high-quality products that will reduce costs in the oncology space."

Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage(R) drug delivery system and iSecure(R) prefilled syringes. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.

                 Private Securities Litigation Reform Act of 1995 --
                  A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Reports Second-Quarter 2009 Results
2. ICU Medical, Inc. to Acquire Hospiras Critical Care Product Line
3. Hospira Receives FDA Approval for Azithromycin for Injection
4. Hospira to Host Conference Call for Second-Quarter 2009 Results
5. Hospira Highlights Five Years of Progress and Future Opportunities at Its 2009 Annual Meeting of Shareholders
6. Hospira to Present at Bank of America and Merrill Lynch 2009 Health Care Conference May 13
7. Hospira Launches Biologics Clock and Web Resource to Raise Awareness of Potential Biogenerics Impact
8. Hospira Reports First-Quarter 2009 Results
9. Hospira to Host Conference Call for First-Quarter 2009 Results
10. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
11. Hospira Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers ... and wrinkles. Few people know that popular cosmetic fillers can enhance ... who is medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... ... to manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , ... often go untreated. , Certain Dri created this infographic to explain the seven ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park ... financial planning services to families and business owners in the greater Kansas City ... children with developmental disabilities. , The Lakemary Center is a comprehensive educational resource ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. ... website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President ... the field of biosimilars through thought leader interaction in, live video and interactive ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
(Date:1/18/2017)... 2017 Ximbio, a non-profit online one-stop-shop ... has opened its first North American headquarters in Kendall Square, ... ... Ximbio following its launch in October 2014 as a business ... commercialization arm of the foundation Cancer Research UK. ...
(Date:1/18/2017)... Drug Administration CSL CureVac Daiichi Sankyo ... Administration FORT Fresenius Pharmaceuticals Gamma Vaccines ... GlaxoWellcome Global Influenza Programme Grippol ... Systems Indian Association of Paediatrics Janssen Pharmaceuticals ... Krka Pharmaceuticals Medicago Medicare MedImmune ...
Breaking Medicine Technology: